Record H1 2025 results with revenue nearly doubling and operational turnaround underway, supported by improved biological performance and cost reductions. Positive EBITDA is targeted by late 2026, with financing initiatives in place to fund operations and expansion.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.